Skip to content
value.today

Proteus Biomedical Inc.

Formerly Vivomems, Inc.

Total raised
$162 M
3 rounds on record
Latest round
$120 M
May 2014
First round on record
Dec 2009
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Proteus Biomedical Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2014$120 MNo. 3$50 to $250 million

Proteus Biomedical Inc.: Raise no. 3, May 2014

Investors in this round

11 investors had bought by the notice of Jun 10, 2014: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$120 M of $200 M offered; $81 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,370,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew M. Thompson · Executive Officer, Director
  • Anthony J. Levitan · Executive Officer
  • Ben M. Costello · Executive Officer
  • David M. O'Reilly · Executive Officer
  • Donald J. Cowling · Executive Officer
  • George M. Savage · Executive Officer
  • Mark J. Zdeblick · Executive Officer
  • Markus J. Christen · Executive Officer
  • Alan J. Levy · Director
  • Frank J. Fischer · Director
  • Immanuel J. Thangaraj · Director
  • Jonathan J. Symonds · Director
  • Myrtle J. Potter · Director
  • Robert J. Epstein · Director
  • Ryan J. Schwarz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • WB Resources, LLC · Boca Raton, FloridaSold in no state named, and outside the US

Remarks in the notice

  • On fees: “Consists of cash and warrants to purchase Series G Stock.”

Signed by Andrew Thompson, President & CEO. Source: SEC Form D, newest notice filed Jun 10, 2014. Read the notice at the SEC.

equitySEC
May 2012$18 MNo. 2$10 to $50 million

Proteus Biomedical Inc.: Raise no. 2, May 2012

Investors in this round

3 investors had bought by the notice of May 16, 2012: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$18 M of $50 M offered; $33 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Thompson · Executive Officer, Director
  • Benjamin L. Costello · Executive Officer
  • David O'Reilly · Executive Officer
  • Erika L. Karplus · Executive Officer
  • George Savage · Executive Officer
  • Joy Berberich · Executive Officer
  • Lorenzo L. Di Carlo · Executive Officer
  • Mark Zdeblick · Executive Officer, Director
  • Timothy L. Robertson · Executive Officer
  • Todd Thompson · Executive Officer
  • Alan Levy · Director
  • Ben Pless · Director
  • Frank Fischer · Director
  • Immanuel Thangaraj · Director
  • Ryan Schwarz · Director
  • Terry Gould · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Thompson, Ceo. Source: SEC Form D, newest notice filed May 16, 2012. Read the notice at the SEC.

equitySEC
Dec 2009$25 MNo. 1$10 to $50 million

Proteus Biomedical Inc.: Raise no. 1, Dec 2009

Investors in this round

9 investors had bought by the notice of Dec 31, 2009: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $35 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Thompson · Executive Officer, Director
  • David O'Reilly · Executive Officer
  • George Savage · Executive Officer
  • Joy Berberich · Executive Officer
  • Mark Zdeblick · Executive Officer, Director
  • Todd Thompson · Executive Officer
  • Alan Levy · Director
  • Ben Pless · Director
  • Frank Fischer · Director
  • Immanuel Thangaraj · Director
  • Ryan Schwarz · Director
  • Terry Gould · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David O'Reilly, Senior Vice President. Source: SEC Form D, newest notice filed Dec 31, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Proteus Biomedical Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2014).

    SEC Form D · Jun 2014

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2014

That is all the official record says: Proteus Biomedical Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Proteus Biomedical Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 11 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Proteus Biomedical Inc.
NameRoleNamed in
Andrew M. ThompsonExecutive officerJun 2014
Anthony J. LevitanExecutive officerJun 2014
Ben M. CostelloExecutive officerJun 2014
David M. O'ReillyExecutive officerJun 2014
Donald J. CowlingExecutive officerJun 2014
George M. SavageExecutive officerJun 2014
Mark J. ZdeblickExecutive officerJun 2014
Markus J. ChristenExecutive officerJun 2014
Andrew ThompsonExecutive officerMay 2012
Benjamin L. CostelloExecutive officerMay 2012
David O'ReillyExecutive officerMay 2012
Erika L. KarplusExecutive officerMay 2012
George SavageExecutive officerMay 2012
Joy BerberichExecutive officerMay 2012
Lorenzo L. Di CarloExecutive officerMay 2012
Mark ZdeblickExecutive officerMay 2012
Timothy L. RobertsonExecutive officerMay 2012
Todd ThompsonExecutive officerMay 2012
Alan J. LevyDirectorJun 2014
Andrew M. ThompsonDirectorJun 2014
Frank J. FischerDirectorJun 2014
Immanuel J. ThangarajDirectorJun 2014
Jonathan J. SymondsDirectorJun 2014
Myrtle J. PotterDirectorJun 2014
Robert J. EpsteinDirectorJun 2014
Ryan J. SchwarzDirectorJun 2014
Alan LevyDirectorMay 2012
Andrew ThompsonDirectorMay 2012
Ben PlessDirectorMay 2012
Frank FischerDirectorMay 2012
Immanuel ThangarajDirectorMay 2012
Mark ZdeblickDirectorMay 2012
Ryan SchwarzDirectorMay 2012
Terry GouldDirectorMay 2012